Acetylsalicylic Acid Daily Vs Acetylsalicylic Acid Every 3 Days In Healthy Volunteers: Effect On Platelet Aggregation, Gastric Mucosa, And Prostaglandin E-2 Synthesis

dc.creatorFreitas Ferreira
dc.creatorPlinio Minghin; Gagliano-Juca
dc.creatorThiago; Zaminelli
dc.creatorTiago; Sampaio
dc.creatorMarinalva Ferreira; Blackler
dc.creatorRory Willian; Trevisan
dc.creatorMiriam da Silva; Novaes Magalhaes
dc.creatorAntonio Frederico; De Nucci
dc.creatorGilberto
dc.date2016
dc.datejul
dc.date2017-11-13T11:35:01Z
dc.date2017-11-13T11:35:01Z
dc.date.accessioned2018-03-29T05:49:08Z
dc.date.available2018-03-29T05:49:08Z
dc.identifierJournal Of Clinical Pharmacology. Wiley-blackwell, v. 56, p. 862 - 868, 2016.
dc.identifier0091-2700
dc.identifier1552-4604
dc.identifierWOS:000380051300010
dc.identifier10.1002/jcph.685
dc.identifierhttp://onlinelibrary-wiley-com.ez88.periodicos.capes.gov.br/doi/10.1002/jcph.685/full
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/326532
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1363538
dc.descriptionSubstantial platelet inhibition was observed 3 days after a single administration of acetylsalicylic acid 81 mg to healthy volunteers. Here we investigate prostaglandin E-2 (PGE(2)) antrum concentrations and gastrointestinal symptoms in two treatment groups: one receiving losartan and acetylsalicylic acid every day and the other receiving losartan every day and acetylsalicylic acid every 3 days. Twenty-eight healthy volunteers from both sexes received either 50 mg losartan and acetylsalicylic acid 81 mg daily or 50 mg losartan and acetylsalicylic acid 81 every 3 days with placebo on the other days. Therapy was delivered for 30 days for both groups. Gastric endoscopy was performed before and after treatment period. Biopsies were collected for PGE2 quantification. Platelet function tests were carried out before and during treatment and TXB2 release on platelet rich plasma was measured. The every 3 day low-dose acetylsalicylic acid regimen produced complete inhibition of platelet aggregation compared to the daily treatment. Thromboxane B2 release was substantially abolished for both groups during treatment. There was no significant difference on the endoscopic score of both treatment groups after the 30-day treatment (P = .215). There was over 50% suppression of antrum PGE2 content on volunteers receiving acetylsalicylic acid daily (P = .0016), while for the every 3 day dose regimen there was no significant difference between pre and post-treatment antrum PGE2 dosages (P = .4193). Since PGE2 is involved in gastric healing, we understand that this new approach could be safer and as efficient as the standard daily therapy on a long-term basis.
dc.description56
dc.description7
dc.description862
dc.description868
dc.languageEnglish
dc.publisherWiley-Blackwell
dc.publisherHoboken
dc.relationJournal of Clinical Pharmacology
dc.rightsfechado
dc.sourceWOS
dc.subjectAntiplatelet Agents
dc.subjectPge(2)
dc.subjectAcetylsalicylic Acid
dc.subjectLosartan
dc.titleAcetylsalicylic Acid Daily Vs Acetylsalicylic Acid Every 3 Days In Healthy Volunteers: Effect On Platelet Aggregation, Gastric Mucosa, And Prostaglandin E-2 Synthesis
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución